Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.
Here's what you need to know now for Monday, Jan. 22.
Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.
More Immunotherapy Buyouts Likely After Kite Sale
Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.